Evidence map›Paper›PMID 41001230›Full record

ArticleO&G open2024

Acceptance of the Respiratory Syncytial Virus Vaccine in Pregnant Individuals.

Tonya Tucker, Zoe Garvey, David O'Sullivan, Alexandra Loza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in O&G open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tonya TuckerUniversity of Connecticut Obstetrics and Gynecology Residency Program and the University of Connecticut School of Medicine, Farmington, and the Department of Maternal Fetal Medicine and the Department of Research Administration, Hartford Healthcare, Hartford, Connecticut.
Zoe GarveyUniversity of Connecticut Obstetrics and Gynecology Residency Program and the University of Connecticut School of Medicine, Farmington, and the Department of Maternal Fetal Medicine and the Department of Research Administration, Hartford Healthcare, Hartford, Connecticut.
David O'SullivanUniversity of Connecticut Obstetrics and Gynecology Residency Program and the University of Connecticut School of Medicine, Farmington, and the Department of Maternal Fetal Medicine and the Department of Research Administration, Hartford Healthcare, Hartford, Connecticut.
Alexandra LozaUniversity of Connecticut Obstetrics and Gynecology Residency Program and the University of Connecticut School of Medicine, Farmington, and the Department of Maternal Fetal Medicine and the Department of Research Administration, Hartford Healthcare, Hartford, Connecticut.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The respiratory syncytial virus (RSV) vaccine was officially offered to pregnant individuals in 2023-2024, with the purpose of providing immunity to infants and young children. We performed a retrospective review to determine the rate of offering the RSV vaccine and acceptance of the vaccine among patients between 32 0/7 and 36 6/7 weeks of gestation. A prospective survey was administered to examine barriers to RSV vaccination. We identified 206 patients, including 111 (53.8%) who were offered the vaccine and 95 (46.1%) who were not offered the vaccine. Of those who were offered the vaccine, 62 (55.9%) accepted and 49 (44.1%) declined. Individuals who declined had significantly higher rates of declining other vaccines in pregnancy (

Identifiers

PMID41001230
PMCPMC12456475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.